Cargando…

Repurposing Drugs in Small Animal Oncology

SIMPLE SUMMARY: Repurposing drugs in oncology consists of using off-label drugs that are licensed for various non-oncological medical conditions to treat cancer. Repurposing drugs has the advantage of using drugs that are already commercialized, with known mechanisms of action, proven safety profile...

Descripción completa

Detalles Bibliográficos
Autores principales: Giuliano, Antonio, Horta, Rodrigo S., Vieira, Rafael A. M., Hume, Kelly R., Dobson, Jane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817697/
https://www.ncbi.nlm.nih.gov/pubmed/36611747
http://dx.doi.org/10.3390/ani13010139
_version_ 1784864808299921408
author Giuliano, Antonio
Horta, Rodrigo S.
Vieira, Rafael A. M.
Hume, Kelly R.
Dobson, Jane
author_facet Giuliano, Antonio
Horta, Rodrigo S.
Vieira, Rafael A. M.
Hume, Kelly R.
Dobson, Jane
author_sort Giuliano, Antonio
collection PubMed
description SIMPLE SUMMARY: Repurposing drugs in oncology consists of using off-label drugs that are licensed for various non-oncological medical conditions to treat cancer. Repurposing drugs has the advantage of using drugs that are already commercialized, with known mechanisms of action, proven safety profiles, and known toxicology, pharmacokinetics and pharmacodynamics, and posology. In this review, we summarize both the benefits and challenges of repurposing anti-cancer drugs; we report and discuss the most relevant studies that have been previously published in small animal oncology, and we suggest potential drugs that could be clinically investigated for anti-cancer treatment in dogs and cats. ABSTRACT: Repurposing drugs in oncology consists of using off-label drugs that are licensed for various non-oncological medical conditions to treat cancer. Repurposing drugs has the advantage of using drugs that are already commercialized, with known mechanisms of action, proven safety profiles, and known toxicology, pharmacokinetics and pharmacodynamics, and posology. These drugs are usually cheaper than new anti-cancer drugs and thus more affordable, even in low-income countries. The interest in repurposed anti-cancer drugs has led to numerous in vivo and in vitro studies, with some promising results. Some randomized clinical trials have also been performed in humans, with certain drugs showing some degree of clinical efficacy, but the true clinical benefit for most of these drugs remains unknown. Repurposing drugs in veterinary oncology is a very new concept and only a few studies have been published so far. In this review, we summarize both the benefits and challenges of using repurposed anti-cancer drugs; we report and discuss the most relevant studies that have been previously published in small animal oncology, and we suggest potential drugs that could be clinically investigated for anti-cancer treatment in dogs and cats.
format Online
Article
Text
id pubmed-9817697
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98176972023-01-07 Repurposing Drugs in Small Animal Oncology Giuliano, Antonio Horta, Rodrigo S. Vieira, Rafael A. M. Hume, Kelly R. Dobson, Jane Animals (Basel) Review SIMPLE SUMMARY: Repurposing drugs in oncology consists of using off-label drugs that are licensed for various non-oncological medical conditions to treat cancer. Repurposing drugs has the advantage of using drugs that are already commercialized, with known mechanisms of action, proven safety profiles, and known toxicology, pharmacokinetics and pharmacodynamics, and posology. In this review, we summarize both the benefits and challenges of repurposing anti-cancer drugs; we report and discuss the most relevant studies that have been previously published in small animal oncology, and we suggest potential drugs that could be clinically investigated for anti-cancer treatment in dogs and cats. ABSTRACT: Repurposing drugs in oncology consists of using off-label drugs that are licensed for various non-oncological medical conditions to treat cancer. Repurposing drugs has the advantage of using drugs that are already commercialized, with known mechanisms of action, proven safety profiles, and known toxicology, pharmacokinetics and pharmacodynamics, and posology. These drugs are usually cheaper than new anti-cancer drugs and thus more affordable, even in low-income countries. The interest in repurposed anti-cancer drugs has led to numerous in vivo and in vitro studies, with some promising results. Some randomized clinical trials have also been performed in humans, with certain drugs showing some degree of clinical efficacy, but the true clinical benefit for most of these drugs remains unknown. Repurposing drugs in veterinary oncology is a very new concept and only a few studies have been published so far. In this review, we summarize both the benefits and challenges of using repurposed anti-cancer drugs; we report and discuss the most relevant studies that have been previously published in small animal oncology, and we suggest potential drugs that could be clinically investigated for anti-cancer treatment in dogs and cats. MDPI 2022-12-29 /pmc/articles/PMC9817697/ /pubmed/36611747 http://dx.doi.org/10.3390/ani13010139 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Giuliano, Antonio
Horta, Rodrigo S.
Vieira, Rafael A. M.
Hume, Kelly R.
Dobson, Jane
Repurposing Drugs in Small Animal Oncology
title Repurposing Drugs in Small Animal Oncology
title_full Repurposing Drugs in Small Animal Oncology
title_fullStr Repurposing Drugs in Small Animal Oncology
title_full_unstemmed Repurposing Drugs in Small Animal Oncology
title_short Repurposing Drugs in Small Animal Oncology
title_sort repurposing drugs in small animal oncology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817697/
https://www.ncbi.nlm.nih.gov/pubmed/36611747
http://dx.doi.org/10.3390/ani13010139
work_keys_str_mv AT giulianoantonio repurposingdrugsinsmallanimaloncology
AT hortarodrigos repurposingdrugsinsmallanimaloncology
AT vieirarafaelam repurposingdrugsinsmallanimaloncology
AT humekellyr repurposingdrugsinsmallanimaloncology
AT dobsonjane repurposingdrugsinsmallanimaloncology